Helping Experts Accelerate Rare Treatments Act of 2022

Summary

Helping Experts Accelerate Rare Treatments Act of 2022 This bill requires studies on processes for approving drugs that treat rare diseases and conditions. The Government Accountability Office (GAO) must contract with an appropriate entity to study the European Union's process for evaluating the safety and efficacy of such drugs, including any flexibilities or mechanisms that are specific to rare diseases or conditions. The GAO must also conduct a study about the Food and Drug Administration's mechanisms for ensuring that patient and physician perspectives are considered when evaluating and approving drugs for rare diseases or conditions. The GAO must report to Congress the results of these studies.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 1 March 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 1 March 2022

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 1 March 2022

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.